Bill Anderson, Bayer CEO (Krisztian Bocsi/Bloomberg via Getty Images)

'In­fe­ri­or ef­fi­ca­cy' leads to pre­ma­ture end of PhI­II for Bay­er's next-gen blood thin­ner asun­dex­i­an

Bay­er is bring­ing a Phase III tri­al for its blood thin­ner asun­dex­i­an to an ear­ly end af­ter the drug showed “in­fe­ri­or ef­fi­ca­cy” against the con­trol …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.